Inhalation Sciences receives new order worth 60,000 Euro from long-term big pharma client
Inhalation Sciences AB (ISAB) has received a purchase order worth 60,000 EURO (almost 700,000 SEK) from a returning customer – one of the world’s top five generics companies by revenue. The client uses an ISAB PreciseInhale® aerosol generation system in-house as a central part of its R&D on inhaled pharmaceuticals.
The order is for essential spare parts and consumables for the client’s PreciseInhale® system. The client is a long-term customer of ISAB’s with a world-class generics pipeline and robust R&D organisation. Prior to its purchase and installation of PreciseInhale® the client carried out extensive contract research projects with ISAB and also has DissolvIt®, ISAB’s in vitro lung simulation module, installed in-house.
ISAB CEO Manoush Masarrat: “we are proud that PreciseInhale® is such a highly -valued and essential part of our customer’s work – delivering outstanding data and value in a range of projects. When a customer of this calibre returns, it reconfirms the unique benefits and capabilities of the system”.
Read more about PreciseInhale® here
PreciseInhale®' is ISAB’s aerosol generation system that generates exceptionally precise PK lung data from the preclinical to the clinical stages of inhaled drug development. By delivering precise and predictive data early on, PreciseInhale significantly®' reduces risk, costs and ultimately attrition in the later clinical stages of drug development.
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, whether new pollutants or life-saving drugs that power human development.
The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on May 21, 2024.
Tags: